Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

Conditions

• Nonarteritic Anterior Ischemic Optic Neuropathy

Eligibility Criteria

Sex

ALL

Age

21 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• ranibizumab — DRUG
  All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.

Study Details

The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.

Key Dates

First listed

Nov 21, 2007

Start date

Nov 30, 2007

Status verified

Aug 2016

Primary completion

Apr 30, 2009

Completion

Apr 30, 2009

Study Design

Enrollment

2 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Ranibizumab
  To determine the mean change in best corrected visual acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study testing system at 6 months in NAION patients treated as needed (PRN) with ranibizumab.

Primary Outcome Measure

Change in Visual Acuity [ Time Frame: Baseline and 6 months ]

Locations (1)

Find similar trials in Aurora, CO